Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

Hepatorenal syndrome.

Ludwig Kramer1, Walter H Hörl

  • 1Department of Medicine IV, Division of Nephrology, University of Vienna Medical School, Austria. Ludwig.kramer@akh-wien.ac.at

Seminars in Nephrology
|July 16, 2002
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

[Practical guideline for short bowel syndrome].

Zeitschrift fur Gastroenterologie·2025
Same author

Comparison of Iron Dosing Strategies in Patients Undergoing Long-Term Hemodialysis: A Randomized Controlled Trial.

Clinical journal of the American Society of Nephrology : CJASN·2021
Same author

Outcomes after placement of a SX-ELLA oesophageal stent for refractory variceal bleeding-A national multicentre study.

Liver international : official journal of the International Association for the Study of the Liver·2018
Same author

Pathophysiology and Treatment of Hyperhomocysteinemia in End-Stage Renal Disease Patients.

Hemodialysis international. International Symposium on Home Hemodialysis·2017
Same author

D-lactic acidosis - case report and review of the literature.

Zeitschrift fur Gastroenterologie·2016
Same author

Nonsteroidal Anti-Inflammatory Drugs and the Kidney.

Pharmaceuticals (Basel, Switzerland)·2016

Hepatorenal syndrome, a kidney dysfunction in severe liver disease, involves blood vessel changes leading to reduced kidney filtration. Liver transplantation offers the best recovery, but supportive therapies are under investigation.

Area of Science:

  • Nephrology
  • Hepatology
  • Gastroenterology

Background:

  • Hepatorenal syndrome (HRS) is functional renal failure in advanced liver disease with portal hypertension.
  • Characterized by splanchnic vasodilation and reduced effective arterial blood volume, HRS leads to renal vasoconstriction and decreased glomerular filtration.
  • Two types exist: rapidly progressive (Type I, often with spontaneous bacterial peritonitis) and slower (Type II).

Purpose of the Study:

  • To define hepatorenal syndrome and its underlying pathophysiology.
  • To review current treatment options, including liver transplantation and supportive therapies.
  • To highlight the need for further research into novel interventions.

Main Methods:

  • Literature review of hepatorenal syndrome pathophysiology and treatment.

Related Experiment Videos

  • Analysis of clinical characteristics and outcomes of HRS patients.
  • Evaluation of supportive treatments such as vasoconstrictors and TIPS.

    • Main Results:

    • HRS involves complex hemodynamic changes, including vasodilation and compensatory vasoconstriction impacting renal function.
    • Orthotopic liver transplantation is the most effective treatment, restoring renal function.
    • Supportive therapies (vasoconstrictors, TIPS, RRT) aim to stabilize patients awaiting transplantation, but their definitive role is uncertain.

    Conclusions:

    • Hepatorenal syndrome is a severe complication of liver disease requiring timely intervention.
    • Liver transplantation remains the gold standard treatment for HRS.
    • Further multicenter investigations are crucial to establish the efficacy of supportive treatments for hepatorenal syndrome.